# The Impact of Semaglutide on Metabolic Syndrome: A Case Report

## TL;DR

A 44-year-old man with metabolic syndrome showed significant health improvements after switching from sitagliptin to semaglutide, a GLP-1 receptor agonist.

## Contribution

This case report demonstrates the effectiveness of semaglutide in improving multiple aspects of metabolic syndrome.

## Key findings

- Semaglutide led to significant reductions in glycated hemoglobin and LDL cholesterol.
- The patient experienced improved liver enzyme levels and stable renal function.
- Urine albumin-creatinine ratio also decreased, indicating better kidney health.

## Abstract

This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin. The patient had previously been treated with multiple oral hypoglycemic agents and basal insulin, yet continued to have inadequate glycemic and lipid control. Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function. This case highlights the pleiotropic benefits of GLP-1 receptor agonists and supports their role in the comprehensive management of metabolic syndrome.